Results 41 to 50 of about 4,155 (158)
Arthritis &Rheumatology, EarlyView.Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco +8 more
wiley +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Arthritis &Rheumatology, EarlyView.Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
BMC RheumatologyObjectives To evaluate the progression from non-radiographic axial spondyloarthritis (nr-axSpA) to radiographic axial spondyloarthritis (r-axSpA) in a Chinese cohort, identify associated risk factors in both clinical and imaging arms, and enable risk ...
Rui-Ying Deng +12 more
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic +7 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Graphical Abstract Objective To evaluate the impact of bimekizumab, a dual interleukin (IL)‐17A and IL‐17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non‐radiographic axSpA [nr‐axSpA]) and 2 (radiographic axSpA [r ...
Walter P. Maksymowych +10 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration of two years or less of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between patients with early and established axSpA treated with biologic/targeted synthetic disease ...
Annik Steimer +18 more
wiley +1 more source
Recent advances in managing axial spondyloarthritis [version 1; peer review: 2 approved]
F1000Research, 2020 Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA.
Priyanka Agrawal, Pedro M. Machado
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective Pathologic bone formation in ankylosing spondylitis (AS) is not fully reflected by systemic inflammation, limiting the utility of markers of inflammation for structural damage assessment. This study aimed to identify plasma protein signatures associated with structural damage severity in AS.
Tiantian Sun +9 more
wiley +1 more source
Rheumatology and Therapy, 2023 Axial spondyloarthritis (axSpA) is a chronic, inflammatory rheumatic disease that primarily affects the axial skeleton, often inflicting severe pain, diminished mobility, and a compromised quality of life.
Daniele Mauro +3 more
doaj +1 more source
International Journal of Dermatology, EarlyView.Development and preliminary validation of the Early Sacroiliitis Screening Tool (ESHST), a dermatology‐oriented screening questionnaire for identifying hidradenitis suppurativa patients at increased risk of spondyloarthritis. ABSTRACT Background Hidradenitis suppurativa (HS) is increasingly recognized as a systemic inflammatory disease associated with ...
Umut Bakay +3 more
wiley +1 more source